Tubulis Secures $361M Series C to Advance NaPi2b-Targeting ADC for Ovarian Cancer and Lung Adenocarcinoma
核心洞察
Tubulis (搜索) closed a $361 million Series C financing to expand clinical development of TUB-040, an antibody-drug conjugate targeting NaPi2b (搜索) overexpressed in ovarian cancer (搜索) and lung adenocarcinomas.
TUB-040 is currently in phase 1/2a trials for platinum-resistant ovarian cancer (搜索) and relapsed/refractory non-small cell lung cancer (搜索), having received FDA Fast Track designation in June 2024.
The funding will support expansion into earlier treatment lines and additional tumor indications, while advancing the company's proprietary ADC platform technologies.
Tubulis (搜索) announced the successful closing of a $361 million Series C financing round, marking one of the largest biotechnology funding rounds focused on antibody-drug conjugate (ADC) development. The proceeds will be used to expand the clinical development of TUB-040, the company's lead ADC candidate, into earlier lines of therapy and additional tumor indications.
Lead Candidate Targets High-Need Cancer Populations
TUB-040 targets NaPi2b (搜索), an antigen that is overexpressed in ovarian cancer (搜索) and lung adenocarcinomas. The ADC is currently being evaluated in a phase 1/2a study in patients with platinum-resistant ovarian cancer, as well as relapsed or refractory non-small cell lung cancer (搜索). The U.S. FDA granted TUB-040 Fast Track designation in June 2024, recognizing the significant unmet medical need in these patient populations.
The Fast Track designation reflects the critical need for new treatment options in platinum-resistant ovarian cancer (搜索), a particularly challenging form of the disease where patients have limited therapeutic alternatives. Similarly, the inclusion of relapsed or refractory non-small cell lung cancer (搜索) patients addresses a population with poor prognosis and few remaining treatment options.
Platform Expansion and Pipeline Development
The substantial funding will enable Tubulis (搜索) to advance its broader pipeline beyond TUB-040. The capital will support the development of TUB-030, another clinical-stage ADC candidate, along with several preclinical programs. The company plans to expand its proprietary ADC platform technologies to bring ADCs into novel applications, potentially broadening the therapeutic utility of this drug class.
The investment represents confidence in Tubulis (搜索)' approach to ADC development and its proprietary platform technologies. ADCs have emerged as a promising therapeutic modality in oncology, combining the targeting specificity of monoclonal antibodies with the potent cell-killing capability of cytotoxic payloads.
Strategic Clinical Development Plans
With the Series C funding, Tubulis (搜索) aims to expand TUB-040's clinical development into earlier lines of therapy, potentially reaching patients before they develop resistance to standard treatments. This strategy could significantly expand the addressable patient population and improve treatment outcomes by intervening earlier in the disease course.
The company's focus on expanding into additional tumor indications suggests a broader therapeutic potential for the NaPi2b (搜索) target beyond ovarian cancer (搜索) and lung adenocarcinoma (搜索). This approach could maximize the clinical and commercial value of TUB-040 while addressing unmet needs across multiple cancer types.